Tag: KDC-MN-026

  • Aniracetam

    Pyrrolidinone-class positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with secondary cholinergic, dopaminergic, and serotonergic neuromodulatory activity

    A lipophilic racetam nootropic developed at Hoffmann-La Roche as a cognition enhancer for cerebrovascular and neurodegenerative disorders, distinguished from piracetam by higher potency, oral lipophilicity, AMPA receptor positive allosteric modulation, and multi-target downstream activation of cholinergic, dopaminergic, and serotonergic neurotransmission through pharmacologically active metabolites.

    Abstract

    Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone; Ro 13-5057) is a lipophilic pyrrolidinone derivative of the racetam structural class, originally synthesized at Hoffmann-La Roche in the late 1970s as a more potent and centrally bioavailable analog of piracetam for the treatment of cognitive dysfunction associated with cerebrovascular disease and neurodegenerative dementia. The compound is classified as a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor, a mechanism that slows both channel deactivation and receptor desensitization at synaptic AMPA receptors, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic neurotransmission in cortical and hippocampal circuits critical for learning and memory [1, 2]. Beyond the direct AMPA receptor modulation, aniracetam and its principal active metabolite N-anisoyl-gamma-aminobutyric acid (N-anisoyl-GABA, which accounts for 70 to 80 percent of the metabolic disposition) exert downstream effects on multiple neurotransmitter systems: enhancement of acetylcholine release in the prefrontal cortex and hippocampus via group II metabotropic glutamate receptor modulation; site-specific activation of dopaminergic and serotonergic transmission in the mesocorticolimbic pathway through nicotinic acetylcholine receptor mechanisms; and anxiolytic activity mediated through an interaction between cholinergic, dopaminergic, and serotonergic systems [3, 4, 5]. The pharmacokinetic profile of aniracetam is characterized by rapid and complete gastrointestinal absorption, extremely low systemic bioavailability of the parent compound (approximately 0.2 percent) due to extensive first-pass hepatic hydrolysis, and a plasma elimination half-life of approximately 35 minutes [6, 7]. The parent compound is rapidly cleaved to yield three primary metabolites: N-anisoyl-GABA (70 to 80 percent), 2-pyrrolidinone (20 to 30 percent), and p-anisic acid (20 to 30 percent), each of which has been shown to contribute to the pharmacological activity profile [8]. A comparative open-label study in 276 patients with cognitive disorders demonstrated preservation of neuropsychological parameters for at least 12 months with aniracetam monotherapy and performance comparable to or exceeding cholinesterase inhibitor monotherapy in mildly demented patients [11]. Preclinical pharmacology is extensive and demonstrates cognitive enhancement in scopolamine-induced amnesia, cerebral ischemia, and age-related cognitive decline models; anxiolytic activity in elevated plus-maze, conditioned fear, and social interaction paradigms; neuroprotection against excitotoxicity and ischemic injury; and activation of brain-derived neurotrophic factor synthesis [12, 13, 14]. The compound was marketed as a prescription medicine in Japan (Draganon, subsequently withdrawn), in Italy (Ampamet), and in Greece (Memodrin, Referan) for cognitive impairment associated with cerebrovascular disease and neurodegenerative conditions. It is not approved by the United States Food and Drug Administration and is not a controlled substance in the United States, where it is sold as a research compound. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.